

TALi Appoints Former Cochlear Executive As New Chief Medical Officer
Global Clinical Affairs Head Joins Digital Therapeutics Leader

TALi Digital Ltd (ASX: TD1, "TALi" or "the Company") is pleased to advise it has appointed Mary Elizabeth Brinson as its new Chief Medical Officer. Dr Brinson was former Vice President, Global Clinical Affairs, with medical devices leader Cochlear Limited (ASX: COH).

Mary Beth holds a Doctorate in Audiology from the University of Louisville in Kentucky, a Master of Business Administration from Rutgers University in New Jersey and a Bachelor's degree in Audiology and Speech Pathology from the University of Georgia in the United States.

Mary Beth has held a number of senior clinical roles during a 16-year career at Cochlear including Director of Quality, Clinical and Regulatory Services and Director of Clinical Services, Research and Professional Training. She is a qualified Audiologist and has practiced in healthcare and academia in the U.S. and United Kingdom. She is also an Adjunct Fellow at Macquarie University in Sydney.

"We're thrilled to be able to welcome Mary Beth to the management team," said TALi Chair, Sue MacLeman. "She is joining at a pivotal time as we work toward a submission to the U.S. Food and Drug Administration ahead of a launch in that market next year."

"Mary Beth's background in hearing, itself a cognitive function, provides an excellent foundation for supporting TALi mission to bring the benefits of strong attention to young children. Her experience leading global clinical affairs at Cochlear, one of the world's most successful medical devices businesses, will be invaluable as we work to make the benefits of TALi's innovative digital therapeutic available in other markets."

Dr Brinson will have overall responsibility for all clinical, regulatory and quality activities at TALi, including the clinical development phase of the company's U.S. Strategic License Agreement with Akili and hold the title Chief Medical Officer.

Her appointment took effect 4 April 2022.

Release authorised by:

The Board of TALi Digital Limited

CONTACT

Corporate

Sue MacLeman
Chair
TALi Digital

Investors

Paul McKeon
Investor Relations Manager
TALi Digital

0437 211 200
investors@talidigital.com

1300 082 013
investors@talidigital.com

About TALi Digital

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy, placing TALi at the forefront of improving early intervention for childhood attention and concentration performance. We believe in healthy, happier minds – our vision is to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Learn more at talidigital.com.